P. Trayhurn and J. Beattie, Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ, Proceedings of the Nutrition Society, vol.93, issue.03, pp.329-339, 2001.
DOI : 10.1038/29795

I. Matias, D. Marzo, and V. , Endocannabinoids and the control of energy balance, Trends in Endocrinology & Metabolism, vol.18, issue.1, pp.27-37, 2007.
DOI : 10.1016/j.tem.2006.11.006

D. Marzo, V. Matias, and I. , Endocannabinoid control of food intake and energy balance, Nature Neuroscience, vol.284, issue.5, pp.585-589, 2005.
DOI : 10.1074/jbc.M211248200

D. Marzo, V. Goparaju, S. Wang, L. Liu, J. Batkai et al., Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature, vol.410, issue.6830, pp.822-825, 2001.
DOI : 10.1038/35071088

N. Jamshidi and D. Taylor, Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats, British Journal of Pharmacology, vol.143, issue.6, pp.1151-1154, 2001.
DOI : 10.1038/sj.bjp.0704379

C. Williams and T. Kirkham, Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors, Psychopharmacology, vol.143, issue.3, pp.315-317, 1999.
DOI : 10.1007/s002130050953

M. Gary-bobo, G. Elachouri, J. Gallas, P. Janiak, P. Marini et al., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007.
DOI : 10.1002/hep.21641

B. Poirier, J. Bidouard, C. Cadrouvele, X. Marniquet, B. Staels et al., The anti-obesity effect of rimonabant is associated with an improved serum lipid profile, Diabetes, Obesity and Metabolism, vol.103, issue.1, pp.65-72, 2005.
DOI : 10.1074/jbc.M209033200

R. Trillou, C. Arnone, M. Delgorge, C. Gonalons, N. Keane et al., Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, vol.284, issue.2, pp.345-353, 2003.
DOI : 10.1152/ajpregu.00545.2002

J. Despres, A. Golay, and L. Sjostrom, Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia, New England Journal of Medicine, vol.353, issue.20, pp.2121-2134, 2005.
DOI : 10.1056/NEJMoa044537

V. Gaal, L. Rissanen, A. Scheen, A. Ziegler, O. Rossner et al., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, The Lancet, vol.365, issue.9468, pp.1389-1397, 2005.
DOI : 10.1016/S0140-6736(05)66374-X

S. Engeli and J. Jordan, The endocannabinoid system: Body weight and metabolic regulation, Clinical Cornerstone, vol.8, pp.24-35, 2006.
DOI : 10.1016/S1098-3597(06)80041-4

R. Nogueiras, C. Veyrat-durebex, P. Suchanek, M. Klein, J. Tschop et al., Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats, Diabetes, vol.57, issue.11, pp.2977-2991, 2008.
DOI : 10.2337/db08-0161

D. Osei-hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-white et al., Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, Journal of Clinical Investigation, vol.118, issue.9, pp.3160-3169, 2008.
DOI : 10.1172/JCI34827

M. Bensaid, M. Gary-bobo, A. Esclangon, J. Maffrand, L. Fur et al., The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells, Molecular Pharmacology, vol.63, issue.4, pp.908-914, 2003.
DOI : 10.1124/mol.63.4.908

I. Matias, S. Petrosino, A. Racioppi, R. Capasso, A. Izzo et al., Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.66-78, 2008.
DOI : 10.1016/j.mce.2008.01.026

URL : https://hal.archives-ouvertes.fr/hal-00531993

M. Cote, I. Matias, I. Lemieux, S. Petrosino, N. Almeras et al., Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, Int J Obes (Lond), vol.31, pp.692-699, 2007.

D. Marzo, V. Cote, M. Matias, I. Lemieux, I. Arsenault et al., Changes in plasma endocannabinoid levels in viscerally obese men following a 1??year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors, Diabetologia, vol.35, issue.2, pp.213-217, 2009.
DOI : 10.1007/s00125-008-1178-6

V. Duvivier, L. Delafoy-plasse, V. Delion, P. Lechevalier, L. Bail et al., Beneficial effect of a chronic treatment with rimonabant on pancreatic function and ??-cell morphology in Zucker Fatty rats, European Journal of Pharmacology, vol.616, issue.1-3, pp.314-320, 2009.
DOI : 10.1016/j.ejphar.2009.05.024

L. Getty-kaushik, A. Richard, J. Deeney, S. Krawczyk, O. Shirihai et al., The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets, Obesity, vol.291, issue.Suppl 1, pp.1856-1860, 2009.
DOI : 10.1038/oby.2009.234

Y. Liu, I. Connoley, C. Wilson, and M. Stock, Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice, International Journal of Obesity, vol.29, issue.2, pp.183-187, 2005.
DOI : 10.1038/sj.ijo.0802847

J. Kim, E. Van-de-wall, M. Laplante, A. Azzara, M. Trujillo et al., Obesity-associated improvements in metabolic profile through expansion of adipose tissue, Journal of Clinical Investigation, vol.117, issue.9, pp.2621-2637, 2007.
DOI : 10.1172/JCI31021DS1

P. Degrace, L. Demizieux, J. Gresti, J. Chardigny, J. Sebedio et al., Hepatic steatosis is not due to impaired fatty acid oxidation capacities in C57BL/6J mice fed the conjugated trans-10,cis-12-isomer of linoleic acid, J Nutr, vol.134, pp.861-867, 2004.

J. Folch, M. Lees, S. Stanley, and G. , A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, vol.226, pp.497-509, 1957.

T. Jourdan, L. Djaouti, L. Demizieux, J. Gresti, B. Verges et al., Liver Carbohydrate and Lipid Metabolism of Insulin-Deficient Mice Is Altered by trans-10, cis-12 Conjugated Linoleic Acid, Journal of Nutrition, vol.139, issue.10, 2009.
DOI : 10.3945/jn.109.111062

L. Persegol, B. Verges, M. Foissac, P. Gambert, and L. Duvillard, Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation, Diabetologia, vol.42, issue.Suppl 2, pp.1380-1386, 2006.
DOI : 10.1007/s00125-006-0244-1

P. Degrace, B. Moindrot, I. Mohamed, J. Gresti, Z. Du et al., Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid, The Journal of Lipid Research, vol.47, issue.12, pp.2647-2655, 2006.
DOI : 10.1194/jlr.M600140-JLR200

R. Vettor and C. Pagano, The role of the endocannabinoid system in lipogenesis and fatty acid metabolism, Best Practice & Research Clinical Endocrinology & Metabolism, vol.23, issue.1, pp.51-63, 2009.
DOI : 10.1016/j.beem.2008.10.002

R. Trillou, C. Delgorge, C. Menet, C. Arnone, M. Soubrie et al., CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, International Journal of Obesity, vol.28, issue.4, pp.640-648, 2004.
DOI : 10.1038/sj.ijo.0802583

D. Osei-hyiaman, M. Depetrillo, P. Pacher, J. Liu, S. Radaeva et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, Journal of Clinical Investigation, vol.115, issue.5, pp.1298-1305, 2005.
DOI : 10.1172/JCI200523057

H. Ogiwara, T. Tanabe, J. Nikawa, and S. Numa, Inhibition of Rat-Liver Acetyl-Coenzyme-A Carboxylase by Palmitoyl-Coenzyme A. Formation of Equimolar Enzyme-Inhibitor Complex, European Journal of Biochemistry, vol.73, issue.1, pp.33-41, 1978.
DOI : 10.1016/0003-2697(73)90217-0

F. Pi-sunyer, L. Aronne, H. Heshmati, D. J. Rosenstock, and J. , Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients, JAMA, vol.295, issue.7, pp.761-775, 2006.
DOI : 10.1001/jama.295.7.761

K. Kozarsky, M. Donahee, J. Glick, M. Krieger, and D. Rader, Gene Transfer and Hepatic Overexpression of the HDL Receptor SR-BI Reduces Atherosclerosis in the Cholesterol-Fed LDL Receptor-Deficient Mouse, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.20, issue.3, pp.721-727, 2000.
DOI : 10.1161/01.ATV.20.3.721

N. Nijstad, H. Wiersma, T. Gautier, M. Van-der-giet, C. Maugeais et al., Scavenger Receptor BI-mediated Selective Uptake Is Required for the Remodeling of High Density Lipoprotein by Endothelial Lipase, Journal of Biological Chemistry, vol.284, issue.10, pp.6093-6100, 2009.
DOI : 10.1074/jbc.M807683200

M. Bluher, S. Engeli, N. Kloting, J. Berndt, M. Fasshauer et al., Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity, Diabetes, vol.55, issue.11, pp.3053-3060, 2006.
DOI : 10.2337/db06-0812

I. Matias, M. Gonthier, P. Orlando, V. Martiadis, D. Petrocellis et al., Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and ??-Pancreatic Cells and in Obesity and Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.3171-3180, 2006.
DOI : 10.1210/jc.2005-2679

K. Starowicz, L. Cristino, I. Matias, R. Capasso, A. Racioppi et al., Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet, Obesity, vol.15, issue.3, pp.553-565, 2008.
DOI : 10.1038/oby.2007.106

S. Nadler, J. Stoehr, K. Schueler, G. Tanimoto, B. Yandell et al., APRIL 2010 expression of adipogenic genes is decreased in obesity and diabetes mellitus, diabetesjournals.org DIABETES Proc Natl Acad Sci, vol.5997, pp.11371-11376, 2000.

L. Heilbronn, S. Smith, and E. Ravussin, Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus, International Journal of Obesity, vol.28, pp.12-21, 2004.
DOI : 10.1038/sj.ijo.0802853

O. Jbilo, C. Ravinet-trillou, M. Arnone, I. Buisson, E. Bribes et al., The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance, The FASEB Journal, vol.19, pp.1567-1569, 2005.
DOI : 10.1096/fj.04-3177fje

P. Arner, Insulin resistance in type 2 diabetes: role of fatty acids, Diabetes/Metabolism Research and Reviews, vol.16, issue.S2, pp.5-9, 2002.
DOI : 10.1002/dmrr.254

K. Kempf, J. Hector, T. Strate, B. Schwarzloh, B. Rose et al., Immune-mediated Activation of the Endocannabinoid System in Visceral Adipose Tissue in Obesity, Hormone and Metabolic Research, vol.39, issue.8, pp.596-600, 2007.
DOI : 10.1055/s-2007-984459

F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory et al., The endogenous cannabinoid system protects against colonic inflammation, Journal of Clinical Investigation, vol.113, issue.8, pp.1202-1209, 2004.
DOI : 10.1172/JCI200419465

H. Ruan and H. Lodish, Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-??, Cytokine & Growth Factor Reviews, vol.14, issue.5, pp.447-455, 2003.
DOI : 10.1016/S1359-6101(03)00052-2

D. Eon, T. Pierce, K. Roix, J. Tyler, A. Chen et al., The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids, Diabetes, vol.57, issue.5, pp.1262-1268, 2008.
DOI : 10.2337/db07-1186

A. Izzo, F. Piscitelli, R. Capasso, G. Aviello, B. Romano et al., Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding, British Journal of Pharmacology, vol.354, issue.2, pp.451-461, 2009.
DOI : 10.1111/j.1476-5381.2009.00183.x

C. Pagano, C. Pilon, A. Calcagno, R. Urbanet, M. Rossato et al., The Endogenous Cannabinoid System Stimulates Glucose Uptake in Human Fat Cells via Phosphatidylinositol 3-Kinase and Calcium-Dependent Mechanisms, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, pp.4810-4819, 2007.
DOI : 10.1210/jc.2007-0768

D. Lau, B. Dhillon, H. Yan, P. Szmitko, and S. Verma, Adipokines: molecular links between obesity and atheroslcerosis, AJP: Heart and Circulatory Physiology, vol.288, issue.5, pp.2031-2041, 2005.
DOI : 10.1152/ajpheart.01058.2004

K. Schoonjans, B. Staels, and J. Auwerx, The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation, Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol.1302, issue.2, pp.93-109, 1996.
DOI : 10.1016/0005-2760(96)00066-5

B. Gustafson, M. Jack, S. Cushman, and U. Smith, Adiponectin gene activation by thiazolidinediones requires PPAR??2, but not C/EBP?????evidence for differential regulation of the aP2 and adiponectin genes, Biochemical and Biophysical Research Communications, vol.308, issue.4, pp.933-939, 2003.
DOI : 10.1016/S0006-291X(03)01518-3